ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sanofi Pasteur is paying $45 million up front to Lexington, Mass.-based Translate Bio, formerly known as RaNA Therapeutics, to develop messenger RNA (mRNA) vaccines for up to five infectious diseases. The vaccines could allow the body to use its own protein-making machinery to develop an immune response to the proteins translated from the mRNA. Translate could receive up to $760 million in additional milestone payments. Sanofi also has an ongoing partnership with BioNTech to develop cancer immunotherapies based on a similar mRNA technology.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X